Association of the ADIPOQ Rs2241766 and Rs266729 Polymorphisms with Metabolic Syndrome in the Chinese Population: A Meta-analysis

详细信息    查看全文

• 作者：Jun Mei ZHOU^a ; ^¶ ; Author Vitae ; Ming ZHANG^a ; ^¶ ; ; ^{zhangming@szu.edu.cn" class="auth_mail" title="E-mail the corresponding author}Author Vitae ; Shu WANG^b ; Bing Yuan WANG^c ; Cheng Yi HAN^c ; Yong Cheng REN^c ; Lu ZHANG^c ; Hong Yan ZHANG^c ; Xiang Yu YANG^c ; Yang ZHAO^c ; Dong Sheng HU^a
• 关键词：ADIPOQ ; Polymorphisms ; Metabolic syndrome ; Meta-analysis
• 刊名：Biomedical and Environmental Sciences
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：29
• 期：7
• 页码：505-515
• 全文大小：8745 K

文摘

This meta-analysis was performed to summarize the association of the ADIPOQ rs2241766 and rs266729 polymorphisms with metabolic syndrome (MS) in the Chinese population.

Methods

We searched for articles in MEDLINE via PubMed, EMBASE, HuGE Navigator, CNKI, and Wanfang databases and calculated odds ratios (ORs) with 95% confidence intervals (CIs) to determine the strength of associations in fixed- or random-effects models.

Results

a30">We included 21 articles in the meta-analysis: 17 reports of ADIPOQ rs2241766 with 3628 cases and 3000 controls and 8 of rs266729 with 2021 cases and 2226 controls. We found an increased risk of MS with the ADIPOQ rs2241766 polymorphism in some genetic models (allele model: OR=1.12, 95% CI: 1.03–1.21; dominant model: OR=1.15, 95% CI: 1.04–1.28; homozygote model: OR=1.22, 95% CI: 1.00–1.49) but no association with the ADIPOQ rs266729 polymorphism (allele model: OR=0.98, 95% CI: 0.82–1.17; dominant model: OR=0.90, 95% CI: 0.79–1.02; recessive model: OR=1.09, 95% CI: 0.85–1.39; homozygote model: OR=1.03, 95% CI: 0.80–1.33).

Conclusion

The results of this meta-analysis suggest an association between the ADIPOQ rs2241766 polymorphism and MS in the Chinese population. G allele of ADIPOQ rs2241766 increases the risk of MS. Better designed studies with different ethnic populations and larger sample sizes are needed for assessing the relationship between ADIPOQ rs2241766 and rs266729 polymorphisms and MS in the future.